Sarepta Therapeutics Reports Earnings Miss and Management Transition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy SRPT?
Source: Benzinga
- Earnings Miss: Sarepta Therapeutics reported an adjusted loss of $3.58 per share, significantly worse than Wall Street's estimate of a $1.31 loss, while sales reached $442.93 million, exceeding the consensus of $391.92 million; however, sales fell 33% year-over-year, primarily due to a $273.8 million drop in Elevidys net product revenue following the company's decision to suspend shipments to non-ambulatory patients in June 2025.
- Management Transition: CEO Douglas Ingram announced his plan to retire by the end of 2026 or upon the appointment of his successor, as disclosed in an SEC filing, prompting the company to initiate a search for a new CEO, which could lead to increased stock volatility in the near term.
- Analyst View: While the company has guided for stable PMO revenue in 2026, analyst Sami Corwin expresses hesitation due to concerns over the marketing authorization of Vyondys 53 and Amondys 45 following the recent failure of the ESSENCE trial; William Blair reiterates a Market Perform rating, viewing limited near-term upside potential for the stock.
- Technical Analysis: The stock is currently trading 3.5% below its 20-day simple moving average and 9.8% below its 100-day SMA, indicating a bearish trend in the short to medium term, with an RSI of 50.00 suggesting neutral market sentiment, while a MACD of -0.10 below its signal line at -0.05 indicates bearish pressure, with key resistance at $20.00 and support at $15.00.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to rise
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 17.640
Low
5.00
Averages
20.80
High
45.00
Current: 17.640
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
uniQure Shares Surge Following FDA Official's Departure
- Significant Stock Surge: uniQure's shares surged 31.39% to $18.75 in premarket trading following the announcement of FDA's biologics division head Vinay Prasad's resignation, extending a 33.99% increase from Friday, indicating strong market optimism about the company's future prospects.
- Regulatory Decision Controversy: During Prasad's tenure, he faced criticism for the FDA's rejection of uniQure's Huntington's disease gene therapy application, as the agency recommended a prospective randomized controlled study, adding regulatory uncertainty that could impact uniQure's market outlook.
- Clinical Trial Challenges: The FDA previously indicated that uniQure could pursue accelerated approval without a placebo control due to difficulties in enrolling Huntington's disease patients, reflecting regulatory flexibility for rare diseases, yet this has sparked ongoing debates about clinical trial design.
- Strong Market Reaction: Following the news of Prasad's departure, uniQure's shares reportedly jumped as much as 70% in after-hours trading, reflecting investor expectations for a potential easing of tensions between the company and the FDA, which could pave the way for future product approvals.
See More
FDA Vaccine Chief Vinay Prasad to Depart Agency
- Departure Sparks Market Reaction: FDA vaccine chief Vinay Prasad is set to leave at the end of April, with shares of Moderna (MRNA) rising 3%, uniQure (QURE) soaring 50%, and Sarepta Therapeutics (SRPT) gaining 5% in after-hours trading, indicating a positive market response to his exit.
- Controversial Tenure: During his time, Prasad faced disputes, notably refusing to consider Moderna's flu vaccine application, although the FDA later reversed its stance after Moderna agreed to conduct a follow-up study, highlighting the complexities of his drug review process.
- FDA Scrutiny on uniQure: The FDA recently recommended that uniQure conduct a sham-surgery-controlled study for its gene therapy targeting Huntington's disease, illustrating the challenges Prasad faced in drug evaluations and the tension with companies affecting their R&D timelines.
- Policy Implementation Completed: Prasad's departure is attributed to the completion of all policies he aimed to implement, including a new priority program to expedite application reviews for treatments meeting national priorities, indicating that his objectives at the FDA have largely been achieved.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
Sarepta Launches Duchenne Scholarship Program for 2026-2027
- Scholarship Program Launch: Sarepta Therapeutics has announced the opening of the Route 79 Duchenne Scholarship Program for the 2026-2027 academic year, offering scholarships of up to $5,000 to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings, aimed at supporting the educational aspirations of this unique community.
- Clear Application Criteria: Applicants must be accepted to or enrolled in an accredited college or vocational school in the U.S. and must be diagnosed with Duchenne or have a sibling diagnosed with the condition, ensuring fairness and targeted support for educational opportunities.
- Independent Review Process: Scholarship recipients are selected by an independent committee, which evaluates applications without considering whether the applicant has received treatment from Sarepta, thereby enhancing the program's credibility and transparency in the selection process.
- Historical Impact: Since its inception nine years ago, the Route 79 Scholarship Program has empowered numerous young individuals to pursue their academic dreams, reflecting Sarepta's ongoing commitment to supporting those affected by Duchenne muscular dystrophy and reinforcing its leadership position in precision genetic medicine.
See More
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
uniQure Shares Surge Following FDA Official's Departure
- Significant Stock Surge: uniQure's shares surged 31.39% to $18.75 in premarket trading following the announcement of FDA's biologics division head Vinay Prasad's resignation, extending a 33.99% increase from Friday, indicating strong market optimism about the company's future prospects.
- Regulatory Decision Controversy: During Prasad's tenure, he faced criticism for the FDA's rejection of uniQure's Huntington's disease gene therapy application, as the agency recommended a prospective randomized controlled study, adding regulatory uncertainty that could impact uniQure's market outlook.
- Clinical Trial Challenges: The FDA previously indicated that uniQure could pursue accelerated approval without a placebo control due to difficulties in enrolling Huntington's disease patients, reflecting regulatory flexibility for rare diseases, yet this has sparked ongoing debates about clinical trial design.
- Strong Market Reaction: Following the news of Prasad's departure, uniQure's shares reportedly jumped as much as 70% in after-hours trading, reflecting investor expectations for a potential easing of tensions between the company and the FDA, which could pave the way for future product approvals.
See More
FDA Vaccine Chief Vinay Prasad to Depart Agency
- Departure Sparks Market Reaction: FDA vaccine chief Vinay Prasad is set to leave at the end of April, with shares of Moderna (MRNA) rising 3%, uniQure (QURE) soaring 50%, and Sarepta Therapeutics (SRPT) gaining 5% in after-hours trading, indicating a positive market response to his exit.
- Controversial Tenure: During his time, Prasad faced disputes, notably refusing to consider Moderna's flu vaccine application, although the FDA later reversed its stance after Moderna agreed to conduct a follow-up study, highlighting the complexities of his drug review process.
- FDA Scrutiny on uniQure: The FDA recently recommended that uniQure conduct a sham-surgery-controlled study for its gene therapy targeting Huntington's disease, illustrating the challenges Prasad faced in drug evaluations and the tension with companies affecting their R&D timelines.
- Policy Implementation Completed: Prasad's departure is attributed to the completion of all policies he aimed to implement, including a new priority program to expedite application reviews for treatments meeting national priorities, indicating that his objectives at the FDA have largely been achieved.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
Sarepta Launches Duchenne Scholarship Program for 2026-2027
- Scholarship Program Launch: Sarepta Therapeutics has announced the opening of the Route 79 Duchenne Scholarship Program for the 2026-2027 academic year, offering scholarships of up to $5,000 to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings, aimed at supporting the educational aspirations of this unique community.
- Clear Application Criteria: Applicants must be accepted to or enrolled in an accredited college or vocational school in the U.S. and must be diagnosed with Duchenne or have a sibling diagnosed with the condition, ensuring fairness and targeted support for educational opportunities.
- Independent Review Process: Scholarship recipients are selected by an independent committee, which evaluates applications without considering whether the applicant has received treatment from Sarepta, thereby enhancing the program's credibility and transparency in the selection process.
- Historical Impact: Since its inception nine years ago, the Route 79 Scholarship Program has empowered numerous young individuals to pursue their academic dreams, reflecting Sarepta's ongoing commitment to supporting those affected by Duchenne muscular dystrophy and reinforcing its leadership position in precision genetic medicine.
See More
